What is Erste Group Bank's Forecast for BSX FY2027 Earnings?

Key Points

• Erste Group Bank analyst H. Engel trimmed Boston Scientific's FY2027 EPS estimate to $3.75 from $3.76 in a research report issued May 5.
• Erste's $3.75 forecast is above MarketBeat's current consensus full-year estimate of $3.38 and slightly higher than Boston Scientific's FY2026 guidance of $3.34–$3.41, implying modest expected growth into FY2027.
• Overall analyst sentiment remains constructive with a MarketBeat consensus rating of "Moderate Buy" and an average price target of $93.91, even as several firms have pared back price targets recently.

Boston Scientific Corporation (NYSE:BSX - Free Report) - Equities research analysts at Erste Group Bank dropped their FY2027 earnings estimates for Boston Scientific in a research report issued on Tuesday, May 5th. Erste Group Bank analyst H. Engel now forecasts that the medical equipment provider will post earnings of $3.75 per share for the year, down from their prior estimate of $3.76. The consensus estimate for Boston Scientific's current full-year earnings is $3.38 per share.

Other analysts also recently issued reports about the stock. JPMorgan Chase & Co. dropped their price target on shares of Boston Scientific from $135.00 to $100.00 and set an "overweight" rating on the stock in a research report on Thursday, February 5th. Royal Bank Of Canada reduced their price objective on shares of Boston Scientific from $105.00 to $100.00 and set an "outperform" rating for the company in a research note on Thursday, April 23rd. Oppenheimer set a $90.00 target price on shares of Boston Scientific in a research report on Thursday, April 23rd. Argus upgraded Boston Scientific to a "strong-buy" rating in a research note on Thursday, February 26th. Finally, Stifel Nicolaus decreased their price objective on Boston Scientific from $90.00 to $85.00 and set a "buy" rating on the stock in a report on Tuesday, April 21st. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have assigned a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, Boston Scientific currently has an average rating of "Moderate Buy" and a consensus price target of $93.91.

Boston Scientific Price Performance

Shares of BSX opened at $55.86 on Friday. The company has a debt-to-equity ratio of 0.42, a current ratio of 1.90 and a quick ratio of 1.08. The company has a market cap of $83.02 billion, a P/E ratio of 23.35, a PEG ratio of 1.03 and a beta of 0.62. Boston Scientific has a 12 month low of $54.98 and a 12 month high of $109.50. The stock has a fifty day moving average price of $65.95 and a 200 day moving average price of $83.68.

Boston Scientific (NYSE:BSX - Get Free Report) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 EPS for the quarter, topping the consensus estimate of $0.79 by $0.01. The business had revenue of $5.20 billion for the quarter, compared to analysts' expectations of $5.19 billion. Boston Scientific had a net margin of 17.29% and a return on equity of 19.17%. The company's quarterly revenue was up 11.6% compared to the same quarter last year. During the same quarter last year, the company posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS.

Hedge Funds Weigh In On Boston Scientific

A number of institutional investors and hedge funds have recently bought and sold shares of BSX. Vanguard Group Inc. grew its holdings in Boston Scientific by 0.8% during the 3rd quarter. Vanguard Group Inc. now owns 138,249,447 shares of the medical equipment provider's stock worth $13,497,294,000 after acquiring an additional 1,115,337 shares during the period. Rathbones Group PLC grew its stake in shares of Boston Scientific by 20.9% in the fourth quarter. Rathbones Group PLC now owns 2,759,657 shares of the medical equipment provider's stock valued at $263,133,000 after buying an additional 477,680 shares in the last quarter. Tounjian Advisory Partners LLC bought a new position in shares of Boston Scientific in the 4th quarter valued at about $1,477,000. Kepler Cheuvreux Suisse SA acquired a new position in shares of Boston Scientific during the 3rd quarter worth about $26,955,000. Finally, Andra AP fonden boosted its stake in shares of Boston Scientific by 5,000.0% during the 3rd quarter. Andra AP fonden now owns 19,278 shares of the medical equipment provider's stock worth $1,882,000 after acquiring an additional 18,900 shares during the period. Institutional investors and hedge funds own 89.07% of the company's stock.

Boston Scientific Company Profile

Boston Scientific Corporation NYSE: BSX is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.